



ERIC LIU MD, DENVER, CO (CHIEF MEDICAL ADVISOR SINCE 2013, CO-FOUNDER, AND FORMER CONSULTANT)

Why are you serving on the HNF board?

The reason why myself and Cindy Lovelace started the HNF is because neuroendocrine cancer often traverses other multiple specialty diseases so the diagnosis can be confusing and erroneous. Patients are uninformed and frustrated by a lack of answers or confusing recommendations from multiple physicians.

Therefore, NET continues to be the “mystery disease”. This disease requires the skills of many specialty medical fields: surgery, oncology, endocrinology, gastroenterology, radiology, nuclear medicine, pathology, general medicine, pulmonology, and radiation oncology, and even pediatricians. The fact is that neuroendocrine cancer can be one of the most easily treated cancers, and patients can be managed to live long and productive lives.

Outreach and education are critical. While several organizations provide patients with important education and information and recommend physicians. HNF and the help of other survivors, medical doctors care about making a difference. We can unveil the mystery on this disease and give patients the life they deserve.

About Dr. Eric Liu

Dr. Liu is a surgeon with specialty in neuroendocrine disease. His Education credentials are as follows—Harvard University, Cambridge, MA, AB, 1992-1996, Biochemistry Columbia University, College of Physicians & Surgeons, New York, NY, MD, 1996-2000 Columbia University, Research Fellowship, Mark Hardy, M.D., Islet Transplantation, 2000-2001 New York-Presbyterian Hospital, New York, NY, Residency in General Surgery, 2001-2004, 2007-2009 National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), National Institutes of Health, Senior Clinical Research Fellow, Islet/Autoimmunity Branch, David Harlan, 2004-2007. Uppsala University, Uppsala, Sweden, Fellowship in Neuroendocrine Oncology, Kjell Oberg, 2009. Vanderbilt University, Master of Science Clinical Investigation, 2013.

Dr. Liu was responsible for establishing the first clinical trial of the Gallium 68/Pet Scan to diagnose neuroendocrine tumors in the United States at Vanderbilt. He studied at the

Neuroendocrine Center for Excellence at Uppsala University Hospital in Sweden, the world's leader in NET research, under Dr. Kjell Oberg.

Liu received the National Cancer Institute Paul Calabresi Award for Clinical Oncology, 2010-2012, is a Member, Executive Board, North American Neuroendocrine Tumors Society, 2011-present. Co-Chair, "Neuroendocrine Regional Symposium Conference", NANETS, Nashville, TN, July 2011. Scientific Committee, 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, Bad Berka, Germany, 2011

Dr. Liu lectures across the country and has served as a NET expert in radio/ television media tours. In 2015 he partnered with Dr. Allen Cohn (oncologist) at the Rocky Mountain Cancer Centers in Denver, CO to launch The Neuroendocrine Institute at RMCC. He and his wife Eunice have three children, Ian, Christopher, and Caroline.